| 63.90 Delayed Data As of Oct 11 |  +1.25 / +2.00%Today’s Change | 50.60 Today|||52-Week Range 79.83 | +12.11% Year-to-Date |
| Neogen (NEOG) Lags Q1 Earnings and Revenue Estimates Sep 24 / Zacks.com - Paid Partner Content | Neogen Forms Partnership With IGS to Enhance Beef Profile Sep 20 / Zacks.com - Paid Partner Content |
| Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)? Sep 23 / Zacks.com - Paid Partner Content |
| Previous close | 62.65 |
| Today’s open | 63.45 |
| Day’s range | 63.45 - 65.20 |
| Volume | 148,379 |
| Average volume (3 months) | 229,170 |
| Market cap | $3.4B |
| Earnings growth (last year) | -5.72% |
| Earnings growth (this year) | +5.36% |
| Earnings growth (next 5 years) | +11.00% |
| Revenue growth (last year) | +2.97% |
| P/E ratio | 56.1 |
| Price/Sales | 7.13 |
| Price/Book | 5.26 |
| Today’s change | Today’s % change | |
|---|---|---|
| QDELQuidel Corp | +0.81 | +1.43% |
| MYGNMyriad Genetics Inc | +0.67 | +2.32% |
| --Quidel Corp | +1.50 | +3.00% |
| VCYTVeracyte Inc | +0.54 | +2.18% |
| Next reporting date | December 16, 2019 |
| EPS forecast (this quarter) | $0.32 |
| Annual revenue (last year) | $414.2M |
| Annual profit (last year) | $60.2M |
| Net profit margin | 14.53% |
Sector Health Technology |
Industry Medical Specialties |
President & Chief Executive Officer John E. Adent |
Chief Financial Officer, Secretary & VP Steven James Quinlan |
Corporate headquarters Lansing, Michigan |
